Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT
NCT05846737Phase 2Withdrawn
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- May 2023
- Primary completion
- May 2025
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of anti-BCMA CAR-T in multiple myeloma (MM), sponsored by Institute of Hematology and Blood Diseases Hospital. Planned start May 2023; status: withdrawn.
02
Drugs
anti-BCMA CAR-T
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05846737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05846737.